February 11, 2011 — In patients with severe spasticity related to multiple sclerosis (MS), intrathecal baclofen (ITB) using a programmable, subcutaneously implanted pump can be an effective ...
Objective: To report treatment of spasticity in a spinal cord-injured person with intrathecal morphine after the person developed tolerance to intrathecal baclofen. Method: Spasticity in a 36-year-old ...
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the commercial launch of LYVISPAH ®, a baclofen oral granules (5, 10 and 20 mg ...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Today, CNS Therapeutics announced the FDA approval of Gablofen® (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a ...
Lyvispah is supplied as a strawberry-flavored, dissolvable granular formulation of baclofen. The Food and Drug Administration (FDA) has approved Lyvispah™ (baclofen) oral granules for the treatment of ...
LONDON — Arbaclofen extended-release tablets (Biogen) can decrease spasticity related to multiple sclerosis (MS), with a better safety profile than the commonly used spasticity-fighting drug baclofen, ...
Arbaclofen extended-release (ER) reduced spasticity in patients with multiple sclerosis and was found to be safe and well-tolerated, according to 2 new abstracts presented at the 33rd Annual Meeting ...
Baclofen may be used alone or with other medications. These are not all the possible side effects of Baclofen. Baclofen is a muscle relaxant and antispastic. Each tablet, for oral administration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback